Formulation, in silico, in vitro characterization, cytotoxicity and cellular uptake of cyclodextrin complexes and ion pairing/salt formation with functional excipients (azelaic acid, tartaric acid, and arginine) with raloxifene

With advancements in drug repurposing, the search for effective and less harmful anticancer agents remains a critical endeavor. Raloxifene, although not a typical anticancer drug, holds promise in this context. However, its poor solubility poses a significant challenge to its therapeutic potential and formulation efficiency. Functional excipients such as cyclodextrins (e.g., β-cyclodextrin, hydroxy propyl β-cyclodextrin, and Captisol) and pH-modifying excipients (e.g., tartaric acid, azelaic acid, and arginine) were investigated to enhance solubility, dissolution, cytotoxicity and cellular uptakes employing Caco-2 cell lines through binary solid dispersions. In silico studies suggested the potential for salt formation with raloxifene-azelaic acid and raloxifene-tartaric acid, as well as inclusion complexes with cyclodextrins. Experimental results showed that pH-modifying excipients, particularly tartaric and azelaic acids, significantly improved solubility (up to an 800-fold increase), outperforming cyclodextrins (8-fold increase) compared to the untreated drug. Cytotoxicity studies on the human breast cancer (Michigan cancer foundation, MCF-7) cells revealed that raloxifene-tartaric acid significantly enhanced cell killing, achieving efficacy comparable to the standard anticancer drug Taxol. Additionally, both fluorescence-labeled raloxifene: hydroxy propyl β-cyclodextrin coprecipitated mixtures (Coppt) and raloxifene: tartaric acid Coppt exhibited concentration- and time-dependent cellular uptake, with mean fluorescence intensity increasing significantly at 24 h, indicating rapid internalization and sustained intracellular retention, especially at higher concentrations. More interestingly, the superior cellular uptake was in favor of the latter, indicating the pH-modifying excipient tartaric acid, and these findings correlated well with solubility and dissolution studies.

Authors

Institutions

Publication Details

Journal
International Journal of Pharmaceutics X
Published
2025-05-09
DOI
https://doi.org/10.1016/j.ijpx.2025.100336
Primary Topic
Drug Solubulity and Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Formulation, in silico, in vitro characterization, cytotoxicity and cellular uptake of cyclodextrin complexes and ion pairing/salt formation with functional excipients (azelaic acid, tartaric acid, and arginine) with raloxifene

Zeinab Fathalla, Hamdy Abdelkader, Hend Mohamed Abdel‐Bar, Ali H. Alamri et al.
International Journal of Pharmaceutics X
Drug Solubulity and Delivery Systems
article

Formulation, in silico, in vitro characterization, cytotoxicity and cellular uptake of cyclodextrin complexes and ion pairing/salt formation with functional excipients (azelaic acid, tartaric acid, and arginine) with raloxifene

Zeinab Fathalla, Hamdy Abdelkader, Hend Mohamed Abdel‐Bar, Ali H. Alamri, Adel Al Fatease, Mai E. Shoman
article en

Abstract

With advancements in drug repurposing, the search for effective and less harmful anticancer agents remains a critical endeavor. Raloxifene, although not a typical anticancer drug, holds promise in this context. However, its poor solubility poses a significant challenge to its therapeutic potential and formulation efficiency. Functional excipients such as cyclodextrins (e.g., β-cyclodextrin, hydroxy propyl β-cyclodextrin, and Captisol) and pH-modifying excipients (e.g., tartaric acid, azelaic acid, and arginine) were investigated to enhance solubility, dissolution, cytotoxicity and cellular uptakes employing Caco-2 cell lines through binary solid dispersions. In silico studies suggested the potential for salt formation with raloxifene-azelaic acid and raloxifene-tartaric acid, as well as inclusion complexes with cyclodextrins. Experimental results showed that pH-modifying excipients, particularly tartaric and azelaic acids, significantly improved solubility (up to an 800-fold increase), outperforming cyclodextrins (8-fold increase) compared to the untreated drug. Cytotoxicity studies on the human breast cancer (Michigan cancer foundation, MCF-7) cells revealed that raloxifene-tartaric acid significantly enhanced cell killing, achieving efficacy comparable to the standard anticancer drug Taxol. Additionally, both fluorescence-labeled raloxifene: hydroxy propyl β-cyclodextrin coprecipitated mixtures (Coppt) and raloxifene: tartaric acid Coppt exhibited concentration- and time-dependent cellular uptake, with mean fluorescence intensity increasing significantly at 24 h, indicating rapid internalization and sustained intracellular retention, especially at higher concentrations. More interestingly, the superior cellular uptake was in favor of the latter, indicating the pH-modifying excipient tartaric acid, and these findings correlated well with solubility and dissolution studies.

International Journal of Pharmaceutics XVol. 9
University of Sadat City (EG), King Khalid University (SA), Minia University (EG)
Clean water and sanitation
Openalex Percentile: Top 93%
Drug Solubulity and Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.